(PDF) HA/HSA Co-Modified Erlotinib–albumin

HA/HSA Co-Modified Erlotinib–albumin Nanoparticles for Lung Cancer Treatment

Drug Design, Development and Therapy - New Zealand

doi 10.2147/dddt.s169734

Full Text

Abstract

Available in full text

Categories

Pharmaceutical Science

Date

July 1, 2018

Authors

Publisher

Informa UK Limited

Related search

Poly(d,l-Lactide-Co-Glycolide)–chitosan Composite Particles for the Treatment of Lung Cancer

International Journal of Nanomedicine

Organic Chemistry

Pharmaceutical Science

English

Co-Encapsulation of Curcumin and Doxorubicin in Albumin Nanoparticles Blocks the Adaptive Treatment Tolerance of Cancer Cells

Biophysics Reports

English

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Cancer Research

English

Synthesis and Characterization of Folic Acid-Conjugated Human Serum Albumin (HSA) Nanoparticles for Isoalantolactone Cellular Uptake in HeLa

African Journal of Pharmacy and Pharmacology

English

Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis

International Journal of Nanomedicine

Organic Chemistry

Pharmaceutical Science

English

ILD During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Folic Acid-Modified Ginsenoside Rg5-Loaded Bovine Serum Albumin Nanoparticles for Targeted Cancer Therapy in Vitro and in Vivo

International Journal of Nanomedicine

Organic Chemistry

Pharmaceutical Science

English

Nanoparticles for the Treatment of Lung Cancers

Journal of Young Pharmacists

English

Successful Treatment of Non-Small Cell Lung Cancer With Gefitinib After Severe Erlotinib-Related Hepatotoxicity

Internal Medicine

Internal Medicine

English